A Bayesian Approach to Biological Variation Analysis.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
08 2019
Historique:
received: 26 11 2018
accepted: 13 05 2019
pubmed: 3 7 2019
medline: 17 4 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

Biological variation (BV) data have many applications for diagnosing and monitoring disease. The standard statistical approaches for estimating BV are sensitive to "noisy data" and assume homogeneity of within-participant CV. Prior knowledge about BV is mostly ignored. The aims of this study were to develop Bayesian models to calculate BV that ( We explored Bayesian models with different degrees of robustness using adaptive Student Using the most robust Bayesian approach on a raw data set gave results comparable to a standard approach with outlier assessments and removal. The posterior distribution of the fitted model gives access to credible intervals for all parameters that can be used to assess reliability. Reliable and relevant priors proved valuable for prediction. The recommended Bayesian approach gives a clear picture of the degree of heterogeneity, and the ability to crudely estimate personal within-participant CVs can be used to explore relevant subgroups. Because BV experiments are expensive and time-consuming, prior knowledge and estimates should be considered of high value and applied accordingly. By including reliable prior knowledge, precise estimates are possible even with small data sets.

Sections du résumé

BACKGROUND
Biological variation (BV) data have many applications for diagnosing and monitoring disease. The standard statistical approaches for estimating BV are sensitive to "noisy data" and assume homogeneity of within-participant CV. Prior knowledge about BV is mostly ignored. The aims of this study were to develop Bayesian models to calculate BV that (
METHOD
We explored Bayesian models with different degrees of robustness using adaptive Student
RESULTS
Using the most robust Bayesian approach on a raw data set gave results comparable to a standard approach with outlier assessments and removal. The posterior distribution of the fitted model gives access to credible intervals for all parameters that can be used to assess reliability. Reliable and relevant priors proved valuable for prediction.
CONCLUSIONS
The recommended Bayesian approach gives a clear picture of the degree of heterogeneity, and the ability to crudely estimate personal within-participant CVs can be used to explore relevant subgroups. Because BV experiments are expensive and time-consuming, prior knowledge and estimates should be considered of high value and applied accordingly. By including reliable prior knowledge, precise estimates are possible even with small data sets.

Identifiants

pubmed: 31263036
pii: clinchem.2018.300145
doi: 10.1373/clinchem.2018.300145
doi:

Substances chimiques

Chlorides 0
Triglycerides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

995-1005

Informations de copyright

© 2019 American Association for Clinical Chemistry.

Auteurs

Thomas Røraas (T)

Norwegian Organisation for Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway; thomas.roraas@icloud.com.

Sverre Sandberg (S)

Norwegian Organisation for Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway.
Department of Global Health and Primary Care, Faculty of Medicine and Dentistry, University of Bergen, Norway.
Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.

Aasne K Aarsand (AK)

Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.

Bård Støve (B)

Department of Mathematics, University of Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH